Valencia biomedical company, MannKind, announced Friday that the Tel Aviv Stock Exchange approved listing common shares of MannKind under the ticker symbol MNKD.
MannKind is creator of the insulin treatment, Afrezza, approved by the FDA last year.
Listing on the Israeli exchange represents a dual listing for the company. It’s also listed on the U.S.-based Nasdaq exchange. The listing takes effect Oct. 28.
Shares of the company’s stock are expected to be included in five of the Israeli equity indexes, one of which is a biomed index.
"The new listing also offers an opportunity to expand and diversify our shareholder base by increasing our exposure and improving our accessibility to Israeli investors," said Hakan Edstrom, president and CEO of MannKind.
Alfred Mann, executive chairman, has had a long-standing relationship with the Israeli biotechnology industry, Edstrom said.
